AURORA, ON--(Marketwired - Sep 25, 2014) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at the 2nd Global Life Sciences Conference to be held on October 2, 2014 in Warsaw, Poland, on the trading floor of the Warsaw Stock Exchange. The conference is sponsored by WedBush Europe and WDM Capital. Over 100 of Central and Eastern Europe's top life science institutional investors, funds, and analysts are expected to attend the Conference. 

Robert Verhagen, President and CEO, will give a corporate presentation of the Company's capabilities in the development of novel cancer therapeutics. A copy of the presentation will be made available on the Company's website at www.helixbiopharma.com following completion of Mr. Verhagen's presentation.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".